Upcoming Conferences, Tentative Meeting Schedules, Analyst Day, Public Offerings, and Data Presentations - Analyst Notes on Incyte, NPS Pharmaceuticals, Arrowhead, Novavax and Chelsea Therapeutics
Editor Note: For more information about this release, please scroll to bottom.
NEW YORK, June 17, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding Incyte Corporation (NASDAQ: INCY), NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), Arrowhead Research Corp. (NASDAQ: ARWR), Novavax, Inc. (NASDAQ: NVAX) and Chelsea Therapeutics International Ltd. (NASDAQ: CHTP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3787-100free.
Incyte Corporation Analyst Notes
On June 12, 2014, Incyte Corporation (Incyte) announced that the Company will present at the 9th Annual JMP Securities Healthcare Conference on June 25, 2014, at 11:00 a.m. EDT in New York. The presentation will be webcast live and can be accessed at the Company's Investor Relations website. Incyte informed that a replay of the presentation will also be archived at the same location. The full analyst notes on Incyte are available to download free of charge at:
http://www.analystsreview.com/Jun-17-2014/INCY/report.pdf
NPS Pharmaceuticals, Inc. Analyst Notes
On June 10, 2014, NPS Pharmaceuticals, Inc. (NPS Pharmaceuticals) announced that the US Food and Drug Administration (FDA) has shifted the tentative date for Natpara (rhPTH[1-84]) Advisory Committee Meeting from July 24, 2014 to September 12, 2014. A final date for the advisory committee meeting is expected to be published by FDA in the Federal Register at least 15 days prior to such meeting. The Company confirmed that the Prescription Drug User Fee Act (PDUFA) Action Date of October 24, 2014, remains as scheduled. The full analyst notes on NPS Pharmaceuticals are available to download free of charge at:
http://www.analystsreview.com/Jun-17-2014/NPSP/report.pdf
Arrowhead Research Corp. Analyst Notes
On June 11, 2014, Arrowhead Research Corp. (Arrowhead) announced that it will host its analyst day on June 19, 2014 at 12:30 p.m. EDT to discuss the next RNAi-based clinical candidate which targets a rare liver disease. During the event, a panel of disease area key opinion leaders will present information about the pathophysiology, patient populations, and current treatments for the disease. Additionally, the Company's management will present nonclinical data and provide anticipated timelines for further development. A live webcast of the presentation and its archive can be accessed at the Company's website. The full analyst notes on Arrowhead are available to download free of charge at:
http://www.analystsreview.com/Jun-17-2014/ARWR/report.pdf
Novavax, Inc. Analyst Notes
On June 11, 2014, Novavax, Inc. (Novavax) announced the closing of the underwritten public offering priced on June 5, 2014. Novavax issued 28.75 million shares of its common stock, including 3.75 million shares pursuant to the underwriters' option to purchase additional shares, at a price of $4.00 per share. This resulted in total gross proceeds of $115.0 million prior to the deduction of underwriters' discount and offering expenses. The Company intends to use a portion of the net proceeds to expand the clinical development of its RSV F-protein nanoparticle vaccine candidate through the initiation of a Phase 2 clinical trial in elderly subjects later in 2014. The trial has been added to the Company's commitment to initiate RSV clinical trials in the pediatric and maternal immunization indications in Q4 2014. The Company also intends to use part of the net proceeds for general corporate purposes, advancement of its influenza vaccine candidates, and its pre-clinical research programs, manufacturing and process development activities, expenditures, and other strategic purposes. The full analyst notes on Novavax are available to download free of charge at:
http://www.analystsreview.com/Jun-17-2014/NVAX/report.pdf
Chelsea Therapeutics International Ltd. Analyst Notes
On June 12, 2014, Chelsea Therapeutics International Ltd. (Chelsea Therapeutics) presented an integrated data analysis from two pivotal, multicenter, placebo-controlled, randomized clinical trials for NORTHERA at the 18th International Congress of Parkinson's Disease and Movement Disorders (MDS). The study showed that NORTHERA (droxidopa) had demonstrated an acceptable safety profile and a statistically significant difference in efficacy compared to placebo for improving the symptoms of neurogenic orthostatic hypotension (NOH) in a population comprised chiefly of patients with Parkinson's Disease (PD). Robert A. Hauser, MD, Professor of Neurology, Molecular Pharmacology and Physiology, and Director of the Parkinson's disease and Movement Disorders Center, University of South Florida, said, "Patients on NORTHERA self-reported more improvements in NOH symptoms of dizziness/lightheadedness, feeling faint or the 'feeling that you are going to black out' compared to patients on placebo. Patients on NORTHERA also showed improvements in standing systolic blood pressure at one week compared to patients on placebo." The full analyst notes on Chelsea Therapeutics are available to download free of charge at:
http://www.analystsreview.com/Jun-17-2014/CHTP/report.pdf
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
Share this article